- Home
- VNOM vs KRYS Comparison
VNOM vs KRYS Comparison
Compare VNOM & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | KRYS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.6B |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VNOM | KRYS |
|---|---|---|
| Price | $42.16 | $332.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | $54.85 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.6M | 572.4K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | 1.27 | ★ 3.62 |
| Revenue | ★ $1,395,000,000.00 | $389,130,000.00 |
| Revenue This Year | $69.89 | $38.74 |
| Revenue Next Year | N/A | $32.53 |
| P/E Ratio | ★ $33.25 | $91.95 |
| Revenue Growth | ★ 62.02 | 33.94 |
| 52 Week Low | $35.10 | $142.51 |
| 52 Week High | $51.13 | $382.54 |
Technical Indicators
Market Signals| Indicator | VNOM | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 47.45 |
| Support Level | $40.17 | $246.17 |
| Resistance Level | $41.62 | $377.89 |
| Average True Range (ATR) | 0.99 | 14.97 |
| MACD | -0.13 | -1.75 |
| Stochastic Oscillator | 17.68 | 49.79 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.